Hiba Jebeile1,2, Megan L Gow1,2, Louise A Baur1,2, Sarah P Garnett1,2, Susan J Paxton3, Natalie B Lister1,2. 1. The University of Sydney, Children's Hospital Westmead Clinical School, Westmead, New South Wales, Australia. 2. Institute of Endocrinology and Diabetes and Weight Management Services, The Children's Hospital at Westmead, Westmead, New South Wales, Australia. 3. School of Psychology and Public Health, La Trobe University, Melbourne, Victoria, Australia.
Abstract
IMPORTANCE: Children and adolescents with obesity are at higher risk of developing depression and anxiety, and adolescent dieting is a risk factor for the development of depression. Therefore, determining the psychological effect of obesity treatment interventions is important to consider. OBJECTIVE: To investigate the association between obesity treatment interventions, with a dietary component, and the change in symptoms of depression and anxiety in children and adolescents with overweight/obesity. DATA SOURCES: Searches of MEDLINE, Embase, Cochrane Library, and PsychINFO were conducted from inception to August 2018. Hand searching of references was conducted to identify missing studies. STUDY SELECTION: Obesity treatment interventions, with a dietary component, conducted in children and adolescents (age <18 years) with overweight/obesity, and validated assessment of depression and/or anxiety were included. DATA EXTRACTION AND SYNTHESIS: Data were independently extracted by 1 reviewer and checked for accuracy. Meta-analysis, using a random-effects model, was used to combine outcome data and moderator analysis conducted to identify intervention characteristics that may influence change in depression and anxiety. The meta-analyses were finalized in May 2019. MAIN OUTCOMES AND MEASURES: Change in symptoms of depression and anxiety postintervention and at the latest follow-up. RESULTS: Of 3078 articles screened, 44 studies met inclusion criteria with a combined sample of 3702 participants (age range, 5.6 to 16.6 years) and intervention duration of 2 weeks to 15 months. Studies reported either no change or a statistically significant reduction in symptoms of depression or anxiety. Meta-analyses of 36 studies found a reduction in depressive symptoms postintervention (standardized mean difference [SE], -0.31 [0.04]; P < .001), maintained at follow-up in 11 studies at 6 to 16 months from baseline (standardized mean difference [SE], -0.25 [0.07]; P < .001). Anxiety was reduced postintervention (10 studies; standardized mean difference [SE], -0.38 [0.10]; P < .001) and at follow-up (4 studies; standardized mean difference [SE], -0.32 [0.15]; P = .03). Longer intervention duration was associated with a greater reduction in anxiety (R2 = 0.82; P < .001). Higher body mass index z score at baseline was associated with a greater reduction in depression (R2 = 0.19; P = .03). CONCLUSIONS AND RELEVANCE: Structured, professionally run pediatric obesity treatment is not associated with an increased risk of depression or anxiety and may result in a mild reduction in symptoms. Treatment of weight concerns should be considered within the treatment plan for young people with depression and obesity.
IMPORTANCE: Children and adolescents with obesity are at higher risk of developing depression and anxiety, and adolescent dieting is a risk factor for the development of depression. Therefore, determining the psychological effect of obesity treatment interventions is important to consider. OBJECTIVE: To investigate the association between obesity treatment interventions, with a dietary component, and the change in symptoms of depression and anxiety in children and adolescents with overweight/obesity. DATA SOURCES: Searches of MEDLINE, Embase, Cochrane Library, and PsychINFO were conducted from inception to August 2018. Hand searching of references was conducted to identify missing studies. STUDY SELECTION: Obesity treatment interventions, with a dietary component, conducted in children and adolescents (age <18 years) with overweight/obesity, and validated assessment of depression and/or anxiety were included. DATA EXTRACTION AND SYNTHESIS: Data were independently extracted by 1 reviewer and checked for accuracy. Meta-analysis, using a random-effects model, was used to combine outcome data and moderator analysis conducted to identify intervention characteristics that may influence change in depression and anxiety. The meta-analyses were finalized in May 2019. MAIN OUTCOMES AND MEASURES: Change in symptoms of depression and anxiety postintervention and at the latest follow-up. RESULTS: Of 3078 articles screened, 44 studies met inclusion criteria with a combined sample of 3702 participants (age range, 5.6 to 16.6 years) and intervention duration of 2 weeks to 15 months. Studies reported either no change or a statistically significant reduction in symptoms of depression or anxiety. Meta-analyses of 36 studies found a reduction in depressive symptoms postintervention (standardized mean difference [SE], -0.31 [0.04]; P < .001), maintained at follow-up in 11 studies at 6 to 16 months from baseline (standardized mean difference [SE], -0.25 [0.07]; P < .001). Anxiety was reduced postintervention (10 studies; standardized mean difference [SE], -0.38 [0.10]; P < .001) and at follow-up (4 studies; standardized mean difference [SE], -0.32 [0.15]; P = .03). Longer intervention duration was associated with a greater reduction in anxiety (R2 = 0.82; P < .001). Higher body mass index z score at baseline was associated with a greater reduction in depression (R2 = 0.19; P = .03). CONCLUSIONS AND RELEVANCE: Structured, professionally run pediatric obesity treatment is not associated with an increased risk of depression or anxiety and may result in a mild reduction in symptoms. Treatment of weight concerns should be considered within the treatment plan for young people with depression and obesity.
Authors: Rodrigo S Carraro; Guilherme A Nogueira; Davi Sidarta-Oliveira; Rodrigo S Gaspar; Nathalia R Dragano; Joseane Morari; Vanessa C D Bobbo; Eliana P Araujo; Natalia F Mendes; Ariane M Zanesco; Natalia Tobar; Celso D Ramos; Jéssica M Toscaro; Marcio C Bajgelman; Licio A Velloso Journal: J Neurosci Date: 2021-10-21 Impact factor: 6.709
Authors: Joseph Firth; Marco Solmi; Robyn E Wootton; Davy Vancampfort; Felipe B Schuch; Erin Hoare; Simon Gilbody; John Torous; Scott B Teasdale; Sarah E Jackson; Lee Smith; Melissa Eaton; Felice N Jacka; Nicola Veronese; Wolfgang Marx; Garcia Ashdown-Franks; Dan Siskind; Jerome Sarris; Simon Rosenbaum; André F Carvalho; Brendon Stubbs Journal: World Psychiatry Date: 2020-10 Impact factor: 49.548
Authors: Wolfgang Marx; Melissa Lane; Meghan Hockey; Hajara Aslam; Michael Berk; Ken Walder; Alessandra Borsini; Joseph Firth; Carmine M Pariante; Kirsten Berding; John F Cryan; Gerard Clarke; Jeffrey M Craig; Kuan-Pin Su; David Mischoulon; Fernando Gomez-Pinilla; Jane A Foster; Patrice D Cani; Sandrine Thuret; Heidi M Staudacher; Almudena Sánchez-Villegas; Husnain Arshad; Tasnime Akbaraly; Adrienne O'Neil; Toby Segasby; Felice N Jacka Journal: Mol Psychiatry Date: 2020-11-03 Impact factor: 15.992
Authors: Megan L Gow; Anna Pham-Short; Hiba Jebeile; Benjamin J Varley; Maria E Craig Journal: Diabetes Metab Syndr Obes Date: 2021-01-18 Impact factor: 3.168
Authors: Anne Claire Grammer; John R Best; Lauren A Fowler; Katherine N Balantekin; Richard I Stein; Rachel P Kolko Conlon; Brian E Saelens; R Robinson Welch; Michael G Perri; Leonard H Epstein; Denise E Wilfley Journal: Ann Behav Med Date: 2021-06-28
Authors: Rajeeb Rashid; Laura Condon; Christian Gluud; Janus C Jakobsen; Jane Lindschou; Inge Lissau Journal: BMJ Open Date: 2020-11-05 Impact factor: 2.692
Authors: Michelle I Cardel; Mark A Atkinson; Elsie M Taveras; Jens-Christian Holm; Aaron S Kelly Journal: JAMA Pediatr Date: 2020-06-01 Impact factor: 16.193